Cullinan Therapeutics, Inc. CGEM Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -44%-12.0pp | -32.1%-1.1pp | -31%— | —— | |
| Return on invested capital | -58%-12.7pp | -45.4%+6.1pp | -51.5%— | —— | |
| Liquidity | |||||
| Current ratio | 10.2×-3.3× | 13.5×-3.5× | 17.1×-4.0× | 21.1×-4.2× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Valuation | |||||
| Market capitalization | $1.08B+140% | $709.21M+62.6% | $436.07M-9.7% | $482.67M-29.6% | |
| Price / book | 1.5×+0.3× | 1.2×+0.2× | 1×+0.1× | 0.9×-0.7× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Cullinan Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Cullinan Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.